BALFAXAR Rapidly Reverses VKA-Induced Anticoagulation1

Image

Head-to-Head VKA Reversal Study

Image

The safety and efficacy of BALFAXAR (n=105) were studied in a head-to-head, randomized, double-blind, multicenter Phase 3 study with Kcentra (n=103) for the reversal of vitamin K antagonist-induced anticoagulation due to the need for urgent surgery (NCT02740335).1

The primary endpoint was hemostatic efficacy rating at the end of the surgery assessed by the Independent Endpoint Adjudication Board (IEAB).1

Image
BALFAXAR was found to be clinically non-inferior to Kcentra, resulting in early study termination at the prespecified interim analysis.1,2
Percentage of patients who achieved effective hemostasis1,2
Image

The median dose of BALFAXAR or Kcentra was 25 IU of factor IX/kg body weight in both treatment groups, ranging from 16 IU/kg to 50 IU/kg in the BALFAXAR group and 15 IU/ kg to 50 IU/kg in the Kcentra group.1

The median duration of the infusion was 12 minutes in the BALFAXAR group (ranging from 8 to 50 minutes) and 13 minutes (ranging from 7 to 30 minutes) in the Kcentra group.1

Image

BALFAXAR was found to be clinically non-inferior to Kcentra, resulting in early study termination at the prespecified interim analysis.1,2

Percentage of patients who achieved effective hemostasis1,2

Image

The median dose of BALFAXAR or Kcentra was 25 IU of factor IX/kg body weight in both treatment groups, ranging from 16 IU/kg to 50 IU/kg in the BALFAXAR group and 15 IU/ kg to 50 IU/kg in the Kcentra group.1

The median duration of the infusion was 12 minutes in the BALFAXAR group (ranging from 8 to 50 minutes) and 13 minutes (ranging from 7 to 30 minutes) in the Kcentra group.1

Image

BALFAXAR Resulted in Rapid and Sustained Reduction in INR

Image

78.1% of patients receiving BALFAXAR vs 71.8% in the Kcentra group had a reduction in INR to ≤1.5 at 30 minutes postinfusion in a randomized, controlled trial1,c

Image

Patients on BALFAXAR had sustained INR reduction to <1.3 for up to 24 hours after infusion1

Image

Learn More About BALFAXAR

Safety Data
Dosing

INR=international normalized ratio.

aMet prespecified non-inferiority criterion (margin used -15% and P<0.001, statistically significant at prespecified alpha level of 0.01). Hemostatic efficacy at the end of surgery was assessed by the blinded Independent Endpoint Adjudication Board using objective criteria.

bDescriptive analysis of all subjects in the study, including an overrun of subjects during the decision making at the interim analysis.

c78.1% in the BALFAXAR group (n=105) vs 71.8% in the Kcentra group (n=103; proportion difference of 6.3%; 95% CI: -5.5%, 18.0%).1

References: 1. BALFAXAR, Prothrombin Complex Concentrate (Human) Full Prescribing Information. Paramus, NJ: Octapharma USA Inc. 2. Sarode R, Goldstein JN, Simonian G, Milling TJ Jr. A phase 3, prospective, randomized, double-blind, multicenter, non-inferiority study comparing two four-factor prothrombin complex concentrates for reversal of vitamin K antagonist-induced anticoagulation in patients needing urgent surgery with significant bleeding risk. Blood. 2022;140(Suppl 1):352-353. doi:10.1182/blood-2022-168890

Important Safety InformationView More +

WARNING: ARTERIAL AND VENOUS THROMBOEMBOLIC COMPLICATIONS

Patients being treated with Vitamin K antagonists (VKA) therapy have underlying disease states that predispose them to thromboembolic events. Potential benefits of reversing VKA should be weighed against the potential risks of thromboembolic events, especially in patients with the history of a thromboembolic

Important Safety InformationView Less —

WARNING: ARTERIAL AND VENOUS THROMBOEMBOLIC COMPLICATIONS

Patients being treated with Vitamin K antagonists (VKA) therapy have underlying disease states that predispose them to thromboembolic events. Potential benefits of reversing VKA should be weighed against the potential risks of thromboembolic events, especially in patients with the history of a thromboembolic event. Resumption of anticoagulation should be carefully considered as soon as the risk of thromboembolic events outweighs the risk of acute bleeding. Both fatal and non-fatal arterial and venous thromboembolic complications have been reported with BALFAXAR in clinical trials and post marketing surveillance. Monitor patients receiving BALFAXAR for signs and symptoms of thromboembolic events. BALFAXAR may not be suitable in patients with thromboembolic events in the prior 3 months.

BALFAXAR is contraindicated in patients with known anaphylactic or severe systemic reactions to BALFAXAR or any of its components. BALFAXAR is also contraindicated in patients with a known allergy to heparin, a history of heparin-induced thrombocytopenia (HIT), and IgA deficient patients with known antibodies against IgA.

In clinical trials, the most frequent (≥3%) adverse reactions observed in subjects receiving BALFAXAR were procedural pain, wound complications, asthenia, anemia, dysuria, procedural vomiting, and catheter-site-related reaction.

BALFAXAR is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.

Indications

BALFAXAR (prothrombin complex concentrate, human-lans) is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with need for an urgent surgery/invasive procedure.

Please click here for Full Prescribing Information, including BOXED WARNING.

To report suspected adverse reactions, contact Octapharma USA, Inc. at 1-866-766-4860 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.